Latest Product Development News

CurveBeam AI has secured nearly half of its A$5 million placement at $0.02 per share, issuing 120 million shares to key investors while awaiting the remainder of funds from Intellivision Holdings.

Beonic Limited has completed a three-year turnaround, reporting a profitable FY26 with EBITDA of A$4.0m and a 17.2% margin. The company’s unified spatial analytics platform and new AI product underpin FY27 growth guidance targeting ~A$20m ARR and a 19% EBITDA margin.

Constellation Technologies (ASX:CT1) reported a 5% revenue decline to $1.71 million and a $458,246 net loss for FY26, weighed down by delayed hardware deployments and increased expenses. Recurring subscription revenue grew 22%, reflecting ongoing customer engagement.

Saluda Medical delivered FY26 revenue of US$90.2 million, beating guidance with strong US and international growth, while reporting a flat net loss of US$149.6 million amid ongoing heavy investment. The company’s FDA approval of its CAP24 paddle lead opens a new US surgical market segment.

Swift TV Ltd advanced its commercial rollout with 7,190 devices sold and secured key technology certifications in FY26, while navigating a 22% revenue decline due to legacy contract wind-downs. The company delivered positive EBITDA and raised $2.3 million to fund growth initiatives.

Beonic Limited grew revenue by 5.2% to $23.3 million in FY26, halving its loss and achieving positive operating cash flow, underpinned by a landmark Moroccan airport contract and product innovation.

RocketBoots reported a 9.7% revenue rise to A$724,815 but deepened its net loss to A$6.6 million, driven by heavy investment ahead of a major contract rollout and international growth.

Clinuvel Pharmaceuticals marked its tenth consecutive profit with stable revenues and rising cash reserves, while accelerating U.S. expansion including a Nasdaq uplisting and potential ASX delisting.

ImpediMed reported a 15% revenue increase to $14.6 million in FY26, broadened reimbursement coverage for its SOZO platform to 95% of the US population, and launched new applications in heart health and weight management.

RAS Technology Holdings (ASX:RTH) posted a 34% revenue increase to $28.4 million for FY2026, driven by expansion across all business units and geographic markets including Asia and the UK. Despite this, significant investments in product development and trading capabilities led to a normalized net loss after tax of $0.3 million.

Integrated Research’s FY26 results reveal a sharp 91% drop in net profit amid softer renewals and rising expenses, offset by a 27% jump in cash and a special dividend. The company pushes forward with AI-powered products despite early-stage commercialisation risks.

Me Today Limited delivered a 36% revenue surge to $7.96 million in FY26, cutting its EBITDA loss by 43% and locking in $1.59 million of new capital from major shareholders ahead of October warrant exercises.